Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc (NASDAQ: THTX) is a specialty biopharmaceutical company advancing therapies for HIV complications and oncology conditions. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely information about FDA-approved HIV treatments like EGRIFTA for lipodystrophy and Trogarzo for multidrug-resistant infections, alongside emerging oncology candidates targeting aggressive cancers. Our curated news collection includes earnings reports, partnership announcements, and research breakthroughs.
Key updates cover three focus areas: commercialized HIV therapies, pipeline progress in oncology, and operational developments across North American/European markets. Content types include clinical trial results, regulatory filings, and executive commentary.
Bookmark this page for structured access to Theratechnologies' latest advancements in niche biopharmaceutical solutions. Verify information directly through company filings and press releases for informed decision-making.
Theratechnologies has announced the appointment of John Leasure as Global Commercial Officer and Peter Kowal as Vice President, HIV-U.S. Commercial Operations, effective March 29, 2021. Both professionals bring extensive experience in their respective fields, particularly in HIV and oncology. Leasure aims to enhance global capabilities and growth within the company, while Kowal will focus on sales and reimbursement strategies. These additions are expected to support the development of both commercial assets and the company's pipeline, as noted by CEO Paul Lévesque.
Theratechnologies (NASDAQ: THTX) announced the first patient has received a dose of TH1902, a peptide-drug conjugate aimed at treating sortilin positive solid tumors. This marks a significant step in the company's oncology program, emphasizing the need for targeted cancer therapies. TH1902 has received fast track designation from the FDA and aims to improve treatment options for patients who have not responded to existing therapies. The Phase 1 trial will assess safety and dosing, with plans to enroll more patients once the maximum tolerated dose is determined.
Theratechnologies has announced new data on tesamorelin's positive effects on liver inflammation markers presented at ENDO 2021. A sub-analysis from a 12-month trial involving 61 HIV-infected individuals showed that tesamorelin reduced T-cell and macrophage activity, indicating a potential for better immune regulation. The company is moving toward a proposed Phase 3 trial to evaluate tesamorelin for the treatment of NASH, with plans to enroll approximately 2,000 participants. This data supports its development in a market with no current approved treatments.
Theratechnologies announced promising new pre-clinical data on TH1902, its peptide-drug conjugate targeting SORT1+ solid tumors. Findings will be presented at AACR Annual Meeting 2021 through two e-posters. TH1902 has received FDA fast track designation for advanced solid tumors expressing sortilin. The company secured $1.4 million in funding from the Canadian Cancer Society and the Government of Quebec for research in targeted oncology. A Phase 1 trial is underway, assessing TH1902's safety and anti-tumor activity across multiple cancer types, with enrollment for further trials planned upon establishing maximum tolerated dose.
MONTREAL, Feb. 25, 2021 – Theratechnologies (NASDAQ: THTX) announced that its CEO, Paul Levesque, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on demand from March 9 at 7:00 a.m. ET via the Company’s website and the virtual conference link. It will remain archived for 90 days. Theratechnologies focuses on innovative therapies that address unmet medical needs, reinforcing its commitment to advancing biopharmaceutical solutions.
Theratechnologies (THTX) reported record revenues of $19.1 million for Q4 and $66.1 million for FY2020. The company saw significant growth in net sales, driven by its HIV treatment portfolio, especially EGRIFTA which recorded a 23.1% increase. Trogarzo also showed a 9.2% rise in sales. R&D expenses rose to $18 million, reflecting ongoing clinical developments, including Phase 3 trials for NASH and Phase 1 for TH1902. Despite revenue growth, a net loss of $22.7 million for FY2020 was reported, primarily due to higher operational expenses.
Theratechnologies Inc. (THTX) will release its financial results for the fourth quarter and fiscal year ending November 30, 2020, on February 25, 2021. A conference call is scheduled for the same day at 8:30 a.m. (ET) to discuss these results, hosted by CEO Paul Lévesque. Participants can join via toll-free or international dialing, and a webcast will also be available. An audio replay of the call will be accessible later that day. The company focuses on developing innovative therapies for unmet medical needs.
Theratechnologies (THTX) announced that the FDA has granted fast track designation for TH1902, aimed at treating sortilin positive advanced solid tumors resistant to standard therapies. This status signifies early recognition of TH1902's potential, which addresses significant medical needs. The Phase 1 trial is set to begin in Q2 2021 to assess safety and anti-tumor activity, particularly for cancers like endometrial and triple negative breast cancer, where sortilin receptor expression is noted in 40-90% of cases. The development is supported by a $1.4 million contribution from the Canadian Cancer Society and the Quebec government.
Theratechnologies has successfully closed its bought-deal public offering, issuing 16,727,900 units at US$2.75 per unit, totaling US$46 million in gross proceeds. The offering included an over-allotment option, accounting for 2,181,900 additional units.
Each unit consists of one common share and half a warrant, exercisable until January 19, 2024, at US$3.18 per share. Proceeds will fund research, commercialization initiatives, and other corporate purposes.
Theratechnologies (NASDAQ: THTX) announced that CEO Paul Levesque and CMO Dr. Christian Marsolais will present at the B. Riley Virtual Oncology Investor Conference on January 20, 2021, at 3:30 p.m. ET. The presentation will focus on the company's innovative therapies aimed at addressing unmet medical needs. Interested parties can access the live virtual presentation through the company's website's 'News' section, with a replay available two hours later. For more information, visit theratech.com.
